8:30 am

Conference Registration & Networking

8:45 am Event Introduction

8:50 am Chair’s Welcome, Opening Remarks & Connection Before Content

9:00 am Opening Panel Discussion: Lost In Translation: How Can We Better Counsel Our Scientific Partners to Advance Healthcare

Synopsis

Discussion on the importance of understanding the science behind products in the life sciences industry to be able to gain the trust of CEOs and understand what the issues that our scientific partners care about.

9:40 am Table Discussion: What have you found works when engaging with your scientific partners?

10:00 am

Networking & Refreshments

Environmental, Social Governance Strategy

10:40 am Discover: ESG as a Strategic Value Driver across Stakeholders and the Role of General Counsels and Legal Teams

  • Neena Patil Chief Legal Officer and SVP for Corporate Affairs, Jazz Pharmaceuticals

Synopsis

• Landscape update on ESG and establishing efforts and governing programs
• Going beyond disclosures to embed purpose in your organization, the evolving roles of GCs and legal teams when it comes to ESG and disclosure frameworks and the SEC: legal and corporate governance considerations.
• How the legal team at Jazz Pharmaceuticals went back to basics in order to roadmap
an ESG strategy that helps the organization navigate its purpose

11:00 am Discover: Legal’s Role in Enhancing Life Sciences Companies ESG Strategy

Synopsis

• Who should be held accountable for ESG?
• Infrastructure for ESG moderation to eliminate inconsistencies across life sciences
organizations’ operations
• Leveraging ESG as a recruitment and retention tool

11:20 am Develop: What More Can We Learn from the Legal Leaders Enhancing their ESG Strategy?

  • Neena Patil Chief Legal Officer and SVP for Corporate Affairs, Jazz Pharmaceuticals
  • Elizabeth Hendler Vice President, Chief Employment Counsel, Boston Scientific

Synopsis

Question & Answer Session Facilitated by the Focus Day Leader

11:40 am Action: What Are You Now Going to Do Differently to Establish/Enhance Your ESG Strategy?

Synopsis

Output-Focused Discussion Session

12:00 pm

Networking & Lunch

1:00 pm Discover: Critical Issues in Life Sciences Strategic Partnerships

  • Ahmed Mousa Chief Business Officer & General Counsel, Pieris Pharmaceuticals

Synopsis

  • Overview of key issues to consider in connection with strategic life sciences partnerships that include codevelopment and/or co-commercialization provisions from the biotech perspective
  • Issues to be discussed in connection with co-development topics include funding, decision-making, trial sponsorship, unsponsored work, opt-out and related termination provisions
  •  Issues to be discussed in connection with co-commercialization topics include territory considerations, sales force requirements, profit calculations for co-commercialization

Strategic Partnership

1:20 pm Discover: Harnessing the Fringe Benefits of Strategic Partnerships

  • Chris Moore General Counsel, Umoja Biopharma
  • Karl Dorwart VP, Head of Life Sciences, Health Care & Consumer Staples, Factor

2:00 pm Discover: The deal is done – now what?

  • Karen Gally Vice President, General Counsel, Otsuka America Pharmaceutical

Synopsis

• How to live in an alliance with another company
• Legal to Legal – how your legal function can best support a collaboration
• Disputes along the way and Planning for the end

2:20 pm Develop: What More Can We Learn from the Legal Leaders Excelling in Strategic Partnerships?

  • Ahmed Mousa Chief Business Officer & General Counsel, Pieris Pharmaceuticals
  • Karen Gally Vice President, General Counsel, Otsuka America Pharmaceutical
  • Chris Moore General Counsel, Umoja Biopharma
  • Karl Dorwart VP, Head of Life Sciences, Health Care & Consumer Staples, Factor

Synopsis

Question & Answer Session Facilitated by the Focus Day Leader

2:30 pm Action: What Are You Now Going to Take Back to Your Own Organizations?

Synopsis

Output-Focused Discussion Session

2:50 pm

Networking & Refreshments

Navigating Company Evolution

3:20 pm Discover: Beyond Legal – Navigating the pre-IPO to Public Company Transition

Synopsis

• Life science companies are unique – many life science companies that prepare for an IPO are leanly-staffed, pre-commercial stage and/or managed by an executive team that is not experienced with the IPO process or being a public company
• Pre-IPO and newly-public life science companies can be better prepared to handle the major shift in focus, operations and processes that follows an IPO
• Beyond the legal aspects of an IPO and complying with legal requirements post-IPO, in-house counsel can be key business partners in the transition phase by identifying and helping to mitigate (typically non-legal) pain points earlier in the process

3:40 pm Session Reserved for One Discovery

Synopsis

4:00 pm Develop: What More Can We Learn From the Legal Leaders Navigating Company Evolution?

Synopsis

Question & Answer Session Facilitated by the Focus Day Leader

4:20 pm Closing Panel Discussion: De-Mystifying Mergers & Acquisitions

  • Amiel Gross General Counsel, Center for Breakthrough Medicines
  • Brenda Furlow Executive Vice President, General Counsel and Chief Compliance Officer, Bio-Techne
  • John Schiffhauer Senior Vice President, Legal & Intellectual Property, Zymergen
  • Matthew Daniel Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer, Charles River Laboratories

Synopsis

• What does the industry landscape look like in 2022?
•  What do issues such as a challenging year for biotech stocks and the world learning to live with Covid-19 mean for the world of M&A?
• From inception to closing – what are the lessons our panelists want to impart from every stage of the deal process? (Including practical steps, key considerations, and documentation)

5:00 pm Action: What Are You Now Going to Do Differently When Navigating Company Change?

Synopsis

Output-Focused Discussion Session

5:20 pm Chair’s Closing Remarks & End of Conference Day One